Life sciences CPA services for biotech innovators.
From medical device manufacturers to commercial R&D entities, we provide the strategic guidance and tactical support life sciences and biotech companies need to streamline operations, raise capital, expand globally, and prepare for transactions.
Why life sciences companies choose GreenGrowth.
In a sector defined by complex regulation, capital-intensive cycles, and rapid scientific change, you need more than traditional audit and tax. You need a partner who understands the work.
In the dynamic world of life sciences and biotechnology, GreenGrowth CPAs provides unmatched financial expertise and strategic advisory. We strive to be the best in the eyes of our clients by delivering superior service and demonstrating profound expertise in the sector.
We go beyond traditional audit and tax. Our life sciences CPA professionals are equipped with the specialized knowledge and experience necessary to navigate the unique financial, regulatory, and operational challenges of the industry.
Whether you're streamlining financial operations, raising capital, expanding internationally, or preparing for a merger or acquisition, we provide the strategic guidance and tactical support you need to achieve your objectives. Founders and investors with significant equity positions may also benefit from our high net worth CPA services.
What sets us apart
- Specialized knowledge of life sciences regulation and reporting
- Hands-on guidance through capital raises, M&A, and exits
- Integrated assurance, tax, and advisory under one roof
- Innovative service delivery built for fast-moving science
Preparing for an audit, capital raise, or transaction?
Talk with our life sciences CPA team about your timeline and what to address first.
Expertise across the life sciences spectrum.
From bench research to commercial scale, our experience reaches every corner of the sector.
Your trusted life sciences CPA advisors.
We understand the complexities of operating in a heavily regulated, capital-intensive industry where every milestone matters. Our team brings the breadth and depth needed to develop strategies that meet your requirements effectively and efficiently.
Our commitment to understanding your unique needs, paired with deep industry expertise and an innovative approach to service delivery, makes us the preferred choice for life science businesses seeking to maximize their potential.
Talk to a SpecialistScope of services for life sciences clients.
A full-service approach across assurance, tax, and advisory, designed to support every stage of growth.
Assurance Services
- Audits, Reviews, and Compilations of Financial Statements
- Internal Audits
- Pension and Benefit Plan Review and Audits (ERISA)
- Financial Forecasts and Projections
- Internal Controls Review and Design
- Due Diligence on Acquisitions and Divestitures
- Custom Assurance Services
- Agreed Upon Procedures
- Quality of Earnings
- Reverse Mergers and Recapitalizations
Tax Services
- Tax Return Preparation and Compliance
- Tax Department Outsourcing
- International Taxation Services
- State and Local Taxation Services
- Alternative Minimum Tax Planning
- Federal, State, and Local Tax Planning and Consulting
- Succession Planning
- IRS Examination Assistance
- ASC 740 (FAS 109 and FIN 48)
- Tax Credits and Incentives
- Quality of Earnings
Advisory and Consulting
- IPO Readiness
- Accounting Services
- Bank Financing Assistance
- Valuation Services
- SEC Outsourcing, Post-Transaction Support
- Business Acquisition and Sale Support
- Forensic Accounting
- Fraud Investigations
- Strategic Planning and Profit Enhancement
- Going Private Transactions
- Transaction Advisory Services
- Outsourced CFO Services
- Operation Effectiveness
- Privacy and Compliance
Ready for a CPA that understands biotech?
Connect with our life sciences team to talk through R&D credits, audit readiness, and capital strategy.
Life Sciences CPA FAQs
Answers to common questions from founders, CFOs, and finance leaders at biotech, pharma, medical device, and life sciences companies.
What R&D tax credits are available for biotech and life sciences companies?
Life sciences and biotech companies often qualify for the federal R&D tax credit under IRC Section 41, plus state-level R&D credits in many jurisdictions. Pre-revenue and early-stage companies can also use the R&D credit against payroll taxes under the PATH Act, providing real cash benefit before profitability. Eligible expenses include qualified wages, supplies, contract research, and certain cloud computing costs.
How is revenue recognition different for life sciences companies?
Life sciences revenue recognition under ASC 606 involves complex contracts with milestone payments, collaboration agreements, licensing deals, royalties, and variable consideration. Determining performance obligations, allocating transaction price, and timing recognition requires careful analysis. Companies preparing for IPO or M&A need this done properly to avoid restatement risk.
When should a biotech company start preparing for an audit?
Audit preparation should start months before fieldwork, especially for first-time audits or pre-IPO companies. Key areas include revenue recognition, stock-based compensation valuation, R&D capitalization decisions, cash flow forecasting, internal controls documentation, and SOC reports from key vendors. A specialized life sciences CPA can quarterback this work.
What is IPO readiness for life sciences companies?
IPO readiness for biotech companies includes audited financial statements meeting SEC standards (typically three years), strengthened internal controls, board governance, S-1 financial sections (MD&A, risk factors), stock-based compensation analysis, ASC 606 compliance, and 409A valuations. Most companies start IPO readiness 12 to 24 months before the offering.
How is stock-based compensation accounted for in life sciences?
Stock-based compensation under ASC 718 requires valuation of equity awards (typically using Black-Scholes or Monte Carlo for performance awards), recognition over the vesting period, and detailed disclosure. Biotech companies often use large equity grants, making this a material area for financial statements. 409A valuations also drive strike pricing decisions and must be properly supported.
What financial considerations are unique to medical device and pharma companies?
Medical device and pharma companies face complex issues including inventory reserves and obsolescence, regulatory milestone tracking, clinical trial cost capitalization, royalty and licensing accounting, international transfer pricing, and compliance with FDA-related disclosure requirements. The capital intensity and long development cycles also create unique cash flow and valuation challenges.
Ready to talk about your life sciences business?
Every company is at a different stage of growth. Let's talk through where you are, what you need, and how we can help.
Talk to a Specialist